For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The CCTG SC30 (RATIONAL) trial has been successfully funded through the CIHR fall competition for nearly $1.2 million over four years. The study will investigate treatment options for patients with blood cancers and low antibody levels to determine the best supportive care interventions to prevent serious infections.
The European Society for Medical Oncology (ESMO) has announced that the recipient of the 2025 TAT Honorary Award is Philippe Bedard, Professor of Medicine at the University of Toronto, Staff Medical Oncologist in the Division of Medical Oncology, Director of the Cancer Genomics Program, and a Principal Investigator in the Bras Drug Development Program at the Princess
The Canadian Cancer Trials Group (CCTG) has been awarded $742,052 for the PAC5 clinical trial in the CIHR Fall 2024 Project Grant competition. This phase III trial will test lanreotide for the prevention of one of the most severe complications of pancreatic surgery, postoperative pancreatic fistula (POPF).
“The PAC5 clinical trial has the potential to change the standard of care for postoperative pancreatic fistula prophylaxis, significantly benefiting patients and reducing healthcare system costs,” says CCTG Senior Investigator, Chris O’Callaghan.
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre,open-label,multiarm, biomarker-directed,signal-seeking,umbrella,clinical trial for recurrent IDH mutant,grade 2/3 glioma
The 2024 - 2025 CCTG New Investigator Clinical Trial Practicum is now accepting applications!
